Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

NCT05039658 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

DLBCL

Interventions

DRUG: IBI110 plus sintilimab
DRUG: IBI110

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.